Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) is expected to release its results after the market closes on Wednesday, May 13th. Analysts expect Avenue Therapeutics to post earnings of ($56.25) per share for the quarter.
Avenue Therapeutics Stock Performance
NASDAQ:ATXI opened at $0.52 on Wednesday. Avenue Therapeutics has a 1 year low of $0.15 and a 1 year high of $0.97. The stock has a market cap of $1.71 million, a price-to-earnings ratio of 0.03 and a beta of -0.09. The business has a fifty day moving average of $0.36 and a 200-day moving average of $0.52.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Featured Articles
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
